Investor Library

StemRIMIR Library
December 5, 2024 Timely Disclosure Information StemRIM Announces Patent Registration in Australia for Peptides Related to the HMGB1 Fragment Peptide Redasemtide 
November 13, 2024 Timely Disclosure Information StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock 
November 5, 2024 Timely Disclosure Information StemRIM Announces Patent Registration in Japan for the HMGB1 Peptide Redasemtide 
October 31, 2024 Timely Disclosure Information Presentation Material for Business Plan and Growth Potential 
September 25, 2024 Timely Disclosure Information StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company’s Executive Officers Employees and External Collaborators 
September 25, 2024 Timely Disclosure Information Notice Regarding Appointment of Director Candidates 
September 13, 2024 Presentation Materials Presentation Materials Financial Results for the Fiscal Year Ended July 31 2024 
September 11, 2024 Financial Results Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2024 [Japanese GAAP]  
September 11, 2024 Timely Disclosure Information Notice Regarding Differences between Non-consolidated Results for Fiscal Year Ended July 31 2024 and those for Previous Fiscal Year 
August 9, 2024 Timely Disclosure Information StemRIM Announces Fixed Details of the Issuance of Stock Options to Temporary Employees and External Collaborator 
August 8, 2024 Timely Disclosure Information StemRIM Announces Patent Registration in China for Peripheral Peptides of the HMGB1 Fragment Peptide Redasemtide 
July 26, 2024 Timely Disclosure Information StemRIM Announces Fixed Details of the Issuance of Stock Options to Directors 
July 26, 2024 Timely Disclosure Information StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees 
July 25, 2024 Timely Disclosure Information StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees 
July 25, 2024 Timely Disclosure Information StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Directors